TELA Bio

TELA · NASDAQ

$1.09+$0.1197 (+12.34%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $0.9703

TELA analyst rating

BuyConsensus of 5 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy4
Hold1
Underperform0
Sell0

12-month price target · 8 analysts

Average $2.12 (+95.0% upside)

Low: $1.01
Now: $1.09
High: $3.15

Upgrades and downgrades

The latest rating actions, newest first

TELA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Craig-Hallum	Sep 25, 2026	Initiates	Buy	$2.00	73%
Citizens	Mar 27, 2026	Maintains	Market Outperform	$5.00 → $3.00	42%
Piper Sandler	Mar 25, 2026	Maintains	Neutral	$1.25 → $1.00	43%
Lake Street	Mar 25, 2026	Maintains	Buy	$3.00 → $2.00	36%
Canaccord Genuity	Mar 25, 2026	Maintains	Buy	$4.00 → $2.00	38%
Lake Street	Dec 1, 2025	Maintains	Buy	$6.00 → $3.00	36%
Canaccord Genuity	Nov 18, 2025	Maintains	Buy	$7.00 → $4.00	38%
Piper Sandler	Nov 14, 2025	Maintains	Neutral	$2.00 → $1.25	43%
Citizens	Nov 14, 2025	Maintains	Market Outperform	$7.00 → $5.00	42%

The case for and against

Updated Sep 15, 2026

Bull case

TELA Bio is showing promising growth with Q4/25 revenue up 18% year-over-year, driven by new customer additions, the US launch of larger-sized OviTex PRS products, and international sales growth. Their OviTex unit sales and PRS unit sales also showed healthy increases of 20% and 12%, respectively. Despite falling slightly below gross margin estimates, the company's EPS of ($0.17) was above consensus estimates.

Bear case

TELA Bio is facing significant challenges with their sales force restructuring and strategic challenges, as evidenced by their lowered 2026 outlook and continued contraction in their stock. While their portfolio may offer potential, execution remains a key concern and it may take time for their new strategy to gain traction and drive revenue growth, leading to a cautious outlook on the stock. Furthermore, the company's dependence on regulatory approvals, potential for future losses and dilution, and uncertainty surrounding reimbursement for their products add additional layers of risk for investors to consider.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.